NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®

CompletedN/A

Sponsor: Novo Nordisk A/S

Conditions: Haemophilia A

Interventions: Turoctocog alfa pegol

Countries: Japan

The purpose of this study is to assess the safety and effectiveness of Esperoct® for long-term routine use in patients with Haemophilia A. Participants will get Esperoct® as prescribed by their doctor. The study will last for about 2 years for each participant.

Eligibility overview

Sex: ALL

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
* The decision to initiate treatment with commercially available Esperoct® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
* Diagnosis of haemophilia A in males or females, no age limitation.
* New patients who have not previously been exposed to Esperoct®.

Exclusion Criteria:

* Previous participation in this study. Participation is defined as having given informed consent in this study.
* Known or suspected hypersensitivity to study product or related products.
* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

Locations (20)

Fukuoka, Japan
Gifu, Japan
Gifu, Japan
Iruma-gun, Saitama, Japan
Kamigyo-ku, Kyoto, Japan
Kanagawa, Japan
Kanagawa, Japan
Nara, Japan
Okinawa, Japan
Saitama, Japan
Shiga, Japan
Shizuoka, Japan
Shizuoka, Japan
Tokyo, Japan
Tokyo, Japan
Tokyo, Japan
Tokyo, Japan
Yamagata, Japan
Yamagata, Japan
Yokohama-shi, Kanagawa, Japan